Skip to main content
. 2023 Dec 31;72(6):753–765. doi: 10.33549/physiolres.935129

Fig. 3.

Fig. 3

Cisplatin-treated HK2 cells exosome-derived miR-122 regulates pyroptosis in surrounding cells.

(A–B) The qPCR analysis of miR-122 expression in vivo and in vitro when adding cisplatin treatment. (C) The qPCR analysis of miR-122 expression. (D) IF staining shows expression of caspase-1 (green); Blue fluorescence represents the nucleus (DAPI). Bar, 20 mm. (E) The qPCR analysis of caspase-1, NLRP3, and GSDMD expression. (F–G) WB analysis of caspase-1, NLRP3, and GSDMD expression. (H) The qPCR analysis of miR-122 expression. (I) 3′-UTR base pairing diagram of miR-122 and ELAVL1. (J) Cells are co-transfected with miR-122 mimics/inhibitor and a luciferase reporter containing a fragment of the ELAVL1 3′-UTR harboring either the miR-122 binding site (ELAVL1-3′-UTR-WT) or a mutant (ELAVL1-3′-UTR-MUT). (K–N) The protein expression of ELAVL1 in vivo and in vitro under different processing conditions. Data are shown as mean ± SEM (n=3). Asterisks indicate significant differences from the control (*P < 0.05; **P < 0.01; ***P < 0.001).